Objective To investigate the impact of μ-opioid receptor gene (OPRM1) rs1799971 (A118G) polymorphism in the Zhuang population on the intraoperative remifentanil consumption dose.

Methods A total of 212 patients of Zhuang population undergoing laparoscopic colorectal cancer surgery in Guangxi were selected as the study subjects. After surgery, the patients were divided into AA group (wild-type homozygous), AG group (heterozygous) and GG group (mutant homozygous) based on OPRM1 A118G gene polymorphism. Propofol was used for sedation induction and maintenance during anesthesia, and the analgesic dose of remifentanil was adjusted according to the surgical stress response. The patients′ vital signs were monitored, and the anesthesia time, surgical time and intraoperative propofol target-controlled infusion (TCI) concentration were recorded. The amount of remifentanil used per unit time was calculated.

Results The genotyping of OPRM1 A118G in 212 patients was AA type (50.5%), AG type (41.0%) and GG type (8.5%), and the distribution frequency of the G allele was 29.0%. The consumption of remifentanil during the operation in the AG group and GG group showed signtficant difference compared with that in the AA group (P＜0.05); there was a statistically significant difference in the intraoperative consumption of remifentanil between the AG group and the GG group (P＜0.05). A gene-dose effect was observed in remifentanil consumption among the three groups: the GG group(0.59±0.07) μg/(kg·min) > the AG group (0.42±0.09) μg/(kg·min)>the AA group (0.33±0.07) μg/(kg·min). OPRM1 A118G gene polymorphism was an independent factor influencing intraoperative remifentanil consumption (P＜0.01).

Conclusion OPRM1 A118G polymorphism in the Zhuang population in Guangxi Zhuang autonomous region is associated with the dosage of remifentanil, with patients carrying the G allele requiring higher intraoperative doses of remifentanil.